Baidu
map

Ophthalmology:大量饮用咖啡可能与致盲眼部疾病风险增加有关

2021-06-09 K.K MedSci原创

有强烈青光眼家族史的患者应该减少咖啡因的摄入量。

饮用咖啡或茶,是全世界人们喜爱的饮品之一。大多数研究观察到,在1-4小时内摄入咖啡因后,眼压可能会急性升高,范围在0-4mmHg之间。眼压升高是青光眼的一个风险因素对于青光眼,患者很少或没有症状,直到疾病发展并视力丧失。事实上,全基因组关联研究(GWASs)表明,眼压属于多基因性状,眼压多基因风险评分中得分越高,原发性开角型青光眼(POAG)患病风险可能越高,少数遗传位点也与较高的咖啡因摄入有关。

6月1日,哈佛大学公共健康学院Jihye Kim等研究人员发表在Ophthalmology上的一项研究观察到:咖啡和茶的摄入量与眼压之间存在弱的反向线性关系。当评估不同类型咖啡的摄入量时,使用速溶咖啡和无咖啡因咖啡与较低的眼压有关,而使用问卷调查时,发现饮用含量较高的咖啡因,如研磨咖啡和其他类型的咖啡,与眼压呈弱正相关。

Jihye Kim et al. Intraocular Pressure, Glaucoma, and Dietary Caffeine Consumption.Ophthalmology.DOI:https://doi.org/10.1016/j.ophtha.2020.12.009.

这是一项基于人口的大型研究,评估了习惯性饮用含咖啡因产品和眼压之间的关系。此外,它还探讨了这种关系是否被较高眼压的遗传易感性所改变。以前的研究很少研究习惯性饮用咖啡因饮品对眼压的影响。在一项日本研究中,对多个协变量进行调整后,习惯性饮用咖啡的男性,眼压较低。同样,本文研究发现,在较高的咖啡因摄入量和眼压之间有一个非常温和的反向关系。

这文研究纳入平均年龄为56.8岁的参与者,其中53.8%的参与者是女性,平均眼压为16.0mmHg,大多数参与者(76.4%)是白人,平均咖啡摄入量为1.9杯/天,平均茶摄入量为3.1杯/天。经常喝咖啡和经常喝酒的人往往会经常吸烟。在121374名参与者中,有77906人完成了饮食调查问卷。

十二多万名参与者摄入的咖啡因饮品和眼压的关系

在青光眼问卷的参与者中,研究人员探讨了饮品与青光眼的关系,其中有9229名青光眼患者和188856名对照组参与者参与,研究人员没有观察到茶或咖啡摄入量与青光眼之间的显著关联,也没有发现咖啡、茶和咖啡因的摄入与原发性开角型青光眼有任何关联。

总的来说,咖啡、茶和咖啡因的摄入与较低的眼压有微弱的关联,而这些与青光眼之间是没有相关性的。在眼压升高最具有遗传易感性的人中,较高的咖啡因摄入量与眼压和青光眼的发生率都有正相关关联。

此外,孟德尔随机分析也没有表明喝咖啡对眼压有任何因果关系。眼压多基因风险评分与咖啡因摄入之间存在着相互作用。具体来说,对于那些眼压基因得分低于75%的人来说,饮用含咖啡因的产品与眼压没有什么关系。相反,对于眼压基因得分最高的25%的人来说,每天喝6杯茶与0杯茶相比,眼压高出0.2毫米汞柱,与不摄入咖啡因相比,每天摄入480毫克,眼压高出0.35毫米汞柱。尽管饮用含咖啡因的饮料总体上可能与较高的眼压无关,但对那些具有较高眼压遗传的人来说,情况可能并非如此。

分析还表明,较高的咖啡因摄入量总体上并不增加青光眼风险。然而,那些处于较高眼压遗传倾向的最高的25%的人来说,更多的咖啡因摄入量对青光眼患者不利,与那些不喝或少喝咖啡的人、基因风险评分最低的人相比,那些每天摄入超过321毫克咖啡因、基因风险评分风险最高的人的青光眼患病率高出3.9倍。而对于那些低于眼压基因得分75%的人来说,更多的咖啡因摄入量与青光眼有弱的反向关系。在那些报告有青光眼家族史的人中,更多的咖啡因摄入对开角型青光眼不利。

 

原文出处:

https://www.aaojournal.org/article/S0161-6420(20)31157-X/fulltext#%20

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1821071, encodeId=f59118210e150, content=<a href='/topic/show?id=86241012046d' target=_blank style='color:#2F92EE;'>#饮用咖啡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101204, encryptionId=86241012046d, topicName=饮用咖啡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Tue Mar 22 04:57:05 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943299, encodeId=335b194329907, content=<a href='/topic/show?id=cccee2926dc' target=_blank style='color:#2F92EE;'>#眼部疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72926, encryptionId=cccee2926dc, topicName=眼部疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f9279, createdName=slcumt, createdTime=Sat Jun 12 20:57:05 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776099, encodeId=b7241e76099a2, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Thu Oct 07 08:57:05 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473279, encodeId=4eb014e32797b, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Thu Jun 10 05:57:05 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541468, encodeId=0da9154146826, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu Jun 10 05:57:05 CST 2021, time=2021-06-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1821071, encodeId=f59118210e150, content=<a href='/topic/show?id=86241012046d' target=_blank style='color:#2F92EE;'>#饮用咖啡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101204, encryptionId=86241012046d, topicName=饮用咖啡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Tue Mar 22 04:57:05 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943299, encodeId=335b194329907, content=<a href='/topic/show?id=cccee2926dc' target=_blank style='color:#2F92EE;'>#眼部疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72926, encryptionId=cccee2926dc, topicName=眼部疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f9279, createdName=slcumt, createdTime=Sat Jun 12 20:57:05 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776099, encodeId=b7241e76099a2, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Thu Oct 07 08:57:05 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473279, encodeId=4eb014e32797b, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Thu Jun 10 05:57:05 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541468, encodeId=0da9154146826, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu Jun 10 05:57:05 CST 2021, time=2021-06-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1821071, encodeId=f59118210e150, content=<a href='/topic/show?id=86241012046d' target=_blank style='color:#2F92EE;'>#饮用咖啡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101204, encryptionId=86241012046d, topicName=饮用咖啡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Tue Mar 22 04:57:05 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943299, encodeId=335b194329907, content=<a href='/topic/show?id=cccee2926dc' target=_blank style='color:#2F92EE;'>#眼部疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72926, encryptionId=cccee2926dc, topicName=眼部疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f9279, createdName=slcumt, createdTime=Sat Jun 12 20:57:05 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776099, encodeId=b7241e76099a2, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Thu Oct 07 08:57:05 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473279, encodeId=4eb014e32797b, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Thu Jun 10 05:57:05 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541468, encodeId=0da9154146826, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu Jun 10 05:57:05 CST 2021, time=2021-06-10, status=1, ipAttribution=)]
    2021-10-07 huiwelcome
  4. [GetPortalCommentsPageByObjectIdResponse(id=1821071, encodeId=f59118210e150, content=<a href='/topic/show?id=86241012046d' target=_blank style='color:#2F92EE;'>#饮用咖啡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101204, encryptionId=86241012046d, topicName=饮用咖啡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Tue Mar 22 04:57:05 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943299, encodeId=335b194329907, content=<a href='/topic/show?id=cccee2926dc' target=_blank style='color:#2F92EE;'>#眼部疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72926, encryptionId=cccee2926dc, topicName=眼部疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f9279, createdName=slcumt, createdTime=Sat Jun 12 20:57:05 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776099, encodeId=b7241e76099a2, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Thu Oct 07 08:57:05 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473279, encodeId=4eb014e32797b, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Thu Jun 10 05:57:05 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541468, encodeId=0da9154146826, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu Jun 10 05:57:05 CST 2021, time=2021-06-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1821071, encodeId=f59118210e150, content=<a href='/topic/show?id=86241012046d' target=_blank style='color:#2F92EE;'>#饮用咖啡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101204, encryptionId=86241012046d, topicName=饮用咖啡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Tue Mar 22 04:57:05 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943299, encodeId=335b194329907, content=<a href='/topic/show?id=cccee2926dc' target=_blank style='color:#2F92EE;'>#眼部疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72926, encryptionId=cccee2926dc, topicName=眼部疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f9279, createdName=slcumt, createdTime=Sat Jun 12 20:57:05 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776099, encodeId=b7241e76099a2, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Thu Oct 07 08:57:05 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473279, encodeId=4eb014e32797b, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Thu Jun 10 05:57:05 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541468, encodeId=0da9154146826, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu Jun 10 05:57:05 CST 2021, time=2021-06-10, status=1, ipAttribution=)]

相关资讯

Mol Neurobiol:Lmo4缺失增强了对顺铂诱导的耳蜗凋亡和听力损失的敏感性

顺铂是一种强效化疗药物,能够诱发耳毒性,限制了其临床上的应用。顺铂诱导的氧化应激在耳蜗细胞凋亡中起着诱因作用,之后的亚硝酸盐应激能够导致转录调控因子LIM domain only 4(LMO4)的硝化

Cancer Gene Therapy:CHD1缺失对R0切除的前列腺癌患者的无转移生存产生负面影响并促进体内自发转移

前列腺癌(PCa)患者的治疗结果变化很大,取决于是否发生远处转移。多条染色体缺失与根治性前列腺切除术(RP)后的早期肿瘤标志物PSA复发(生化复发,BCR)有关,但其对远处转移形成的潜在作用在很大程度

Science:单一基因的改变将现代人类与尼安德特人区分开来?

用尼安德特人变体基因构建现代人脑类器官可以一窥该基因中的替代对我们物种演化的影响方式。

Eur Urol:前列腺特异性膜抗原和氟尿嘧啶转运体基因与原发性前列腺癌的不同临床特征和分子亚型有关

在美国,基于8F-氟尿嘧啶的正电子发射断层扫描(PET)成像推荐用于前列腺癌治疗后的生化复发(BCR)。然而,基于前列腺特异性膜抗原(PSMA)的PET成像在世界范围内更为普遍,且由国际指南的支持,目

IEEE J Biomed Health Inform:检测早期轻度认知障碍,遗传进化随机森林法大有可为

该研究设计了脑区与基因融合的方法,并通过相关分析构建融合特征。这种融合特征被称为脑区-基因对(BR-gene)。提出了一种遗传进化随机森林(GERF)方法,以克服少而高维数据和研究框架不完整的限制。

Prostate Cancer P D:CASC11能够促进前列腺癌细胞的侵袭性

前列腺癌是发达国家男性中继肺癌之后最常见的恶性肿瘤。迫切需要对PCa潜在的分子机制进行研究来开发更好的治疗策略和更有效的治疗靶点。

Baidu
map
Baidu
map
Baidu
map